Acetohydroxamic Acid After Incomplete Clearance of a Struvite Stone
A residual struvite fragment and a recurrent Proteus infection that antibiotics alone haven't resolved — and the one drug that reliably slows the stone's growth has a real cost of its own.
Colleen P., a 71-year-old retired schoolteacher, lives alone but sees her son most days, who has taken on managing her medication schedule and driving her to appointments since her husband passed two years ago. She underwent percutaneous nephrolithotomy for a large struvite stone eighteen months ago, and imaging since has shown a residual fragment in a lower-pole calyx that the original procedure could not fully clear. She has had three symptomatic urinary tract infections with Proteus mirabilis in the past year, each treated with a full antibiotic course, and each recurring within a few months. Her most recent CT shows the fragment has grown modestly since her last imaging six months ago. She has a documented deep vein thrombosis in her left leg eleven years ago, provoked by a long postoperative immobilization after a hip replacement, and has otherwise been healthy since.
Struvite stones form because urease-producing bacteria, usually Proteus, hydrolyze urea into ammonia and raise urinary pH and alkalinity to levels that favor further stone formation — a self-sustaining cycle in which the stone itself is both the cause and the ongoing source of the infection. The only drug that directly interrupts that cycle, acetohydroxamic acid, was tested by Williams and colleagues in a randomized, double-blind trial against placebo in patients much like Colleen: eighteen treated patients versus nineteen on placebo, followed for well over a year. None of the treated patients had their stone double in surface area, versus seven of the placebo group — a real, statistically clear effect. But the same trial reported that nine of the eighteen treated patients needed a dose reduction or discontinuation for adverse effects, against one of nineteen on placebo — including tremulousness in five and phlebothrombosis in three. Both of those events occurred only in the treated group, but with eighteen patients in it the clotting difference did not reach statistical significance, and that is the honest status of the number: a signal too small to confirm and too pointed to dismiss, landing on the one detail in Colleen's own history that would otherwise not matter much to this decision at all.
In clinic, after her third Proteus infection this year
She is exactly the patient the AUA guideline describes acetohydroxamic acid for — a residual stone after surgery that hasn't been fully cleared, with ongoing infection. The one real randomized trial we have showed a clear separation from placebo on stone growth: none of eighteen treated patients doubled in size, versus seven of nineteen on placebo. I'd start it.
That same trial is worth reading past the headline result. Nine of those eighteen treated patients needed a dose reduction or discontinuation for adverse effects, against one of nineteen on placebo, and three had phlebothrombosis on the drug.
Colleen has a documented DVT in her history. That's not a population-level statistic to her — it's the specific harm the trial found, landing on the one detail in her chart that makes it personally relevant rather than an abstract side-effect line. I'd continue suppressive antibiotics and accept some growth risk rather than add that specific exposure.
Before we get there — I want to push back on how load-bearing that clotting number has become. Three events in eighteen patients, not statistically significant, is thin. And Colleen's clot was provoked, by postoperative immobilization, eleven years ago, with nothing since. A provoked remote event is not the same risk object as unprovoked or recurrent thrombophilia, and we are treating it as though it were.
That said, I don't think either medical option actually solves her problem. Antibiotics alone haven't stopped the infections from recurring three times this year, and acetohydroxamic acid slows growth without removing the fragment that keeps reseeding the infection in the first place. I'd push for a second attempt at surgical clearance rather than settle for managing around a stone that's going to keep doing this either way.
Not agreed, and left explicitly open rather than resolved: the urologist and infectious disease physician differed on whether repeat surgery or acetohydroxamic acid was the better next step if a formal surgical risk reassessment comes back unfavorable. The clinical pharmacologist maintained that her DVT history should weigh against acetohydroxamic acid regardless of what the surgical reassessment shows; the infectious disease physician's objection — that a non-significant three-event finding is being asked to carry a decision, and that a provoked clot eleven years gone is not the risk it is being treated as — was not withdrawn and not answered.
The one point of agreement: a formal surgical risk reassessment should happen before either medical option is finalized, since the decision looks different depending on whether repeat surgery is genuinely back on the table or not.